Jazz Pharmaceuticals plc reaffirmed earnings guidance for 2015. For 2015, the company does expect to meet prior guidance on the top line. That would represent about 13% or 14% top-line growth over 2014.

The company did ended the year with 6% volume growth and expect to meet financial revenue guidance for the year. The company expects Erwinaze revenues will also meet prior guidance of $200 million to $210 million in sales for 2015.